Articles tagged with Melanoma Cells
Researchers at Kobe University successfully grew precursors for human pigment cells, providing a stable supply of melanocytes for research on melanoma and other pigment cell-related illnesses. These precursor cells can be used to study the causes of albinism, freckles, and melanoma.
A new study reveals that actin, a protein responsible for cell movement, also drives the ability of cancer cells to grow when under stress. Enlarged actin sheets called lamellipodia sequester tumor suppressor molecules, allowing cancer cells to resist chemotherapy and grow more aggressively.
Researchers at H. Lee Moffitt Cancer Center discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. Blocking ITCH activity or BRAF ubiquitination may be an effective treatment approach to slow tumor growth in melanoma.
Research shows that branched actin transmits information to cells about their environment and regulates growth, a mechanism that can be targeted to fight certain types of cancer. Inhibiting branched actin formation prevents the growth of melanoma cells, offering new therapeutic options.
Researchers at the University of Bradford discovered a protein, EN2, released by cancer cells that alters normal cell behavior, promoting tumour growth and evading the immune system. The study found that both cancer and normal cells take up the protein, leading to changes in shape or fusion, allowing cancer cells to reactivate and spread.
Researchers have identified microphthalmia-associated transcription factor (MITF) as a pivotal protein in the maintenance of melanocytes and survival of melanoma cells. A chemical inhibitor of MITF has been found to prevent growth of human melanoma cells, suggesting that MITF expression levels can predict sensitivity to such therapies.
A new study by MD Anderson Cancer Center suggests that certain B cells with unique characteristics can predict which patients are most likely to respond to immunotherapy for metastatic melanoma and kidney cancer. The researchers found that activated B cells with specific phenotypes were associated with a better response to treatment.
Researchers found a promising lead in seriniquone, a natural product isolated from seawater bacteria, to treat melanoma. The compound targets a specific biochemical pathway in melanoma cells and has shown potent activity against the disease.
Researchers at Ben-Gurion University and Texas Southwestern Medical Center developed AI-powered technology to identify melanoma cells with metastatic potential. The technology uses quantitative live cell histology to record video of cells and analyze their appearance and behavioral patterns.
Two new forms of an older anti-cancer agent, s-DAB-IL-2 and s-DAB-IL-2(V6A), have been shown to enhance the immune system's ability to fight melanoma in mice. The agents depleted T regulatory cells and inhibited tumor growth when used individually or in combination with checkpoint blockade therapy.
Researchers discovered that BRAF inhibitors render resistant melanoma cells more sensitive to T cell attack by increasing the expression of a protein called M6PR. This finding suggests that adoptive T cell therapy may be therapeutically useful for patients who have become resistant to BRAF inhibitors.
Scientists have found that invasive skin cancer molecules reprogram healthy immune cells, allowing the cancer to spread. Researchers discovered that blocking certain chemicals can help prevent the aggressive skin cancer from coming back after treatment.
Researchers have discovered a method to 'turn off' mutated melanoma, developing a promising therapeutic option for NRAS mutant cancer. A specific inhibitor targeting the STK19 gene has been designed to prevent NRAS activation and development of NRAS mutant melanoma in an experimental model.
Researchers have identified a cellular mechanism by which cold tumors can be made susceptible to immunotherapy. The study found that inducing UCP2 expression in tumor cells prompts an anti-cancer immune response, drawing killer T cells and conventional type 1 dendritic cells into the microenvironment.
Researchers identified an FDA-approved drug, resperine, that hampers metastasis in animal models by disrupting the uptake of tumor-derived extracellular vesicles by healthy cells. This process prevents cancer cells from seeding and thriving in distant tissues. Resperine's success suggests a potential anti-metastatic therapy strategy.
Researchers at Thomas Jefferson University discovered a compound from Christmas berry primrose plants can inhibit uveal melanoma growth, offering potential new treatments for patients. The compound, FR900359, works by blocking mutated G proteins that promote cancer growth.
A study combining three advanced treatments for malignant melanoma shows promising results in animal models, with the triple combination producing near-total eradication of tumors. The use of oncolytic viruses, MEK inhibitors and immune checkpoint blockers enhances therapeutic responses, offering new hope for patients with melanoma.
Researchers have identified a genetic change common to 80% of human melanomas and developed a molecule that targets this change. The molecule binds to melanocortin-1 receptor (MC1R) on the surface of melanoma cells, allowing for imaging and potential therapy delivery.
Researchers at the University of Tokyo have discovered that blocking a specific molecule can prevent cancer cells from spreading. The study found that inhibiting tissue type plasminogen activator (tPA) blocked melanoma growth and metastasis in mice. This breakthrough offers new possibilities for cancer therapy, potentially improving ou...
Researchers have discovered that metastatic cancer cells follow a Lévy walk movement pattern, like sharks searching for food, which aids in their rapid spread and direction. The team was able to reprogram this behavior using chemical inhibitors, changing it back to more typical diffusive motion
A team of researchers from the University of North Texas Health Science Center discovered a new approach to combating melanoma by targeting the NGLY1 protein. The study found that when normal cells are inhibited, they survive, but cancer cells with low or no NGLY1 activity die quickly.
Researchers identified specific CD8 T cell states associated with patient response to checkpoint immunotherapy for melanoma. The study found that tumors responding to therapy had a higher proportion of stem-cell-like memory CD8 T cells, while non-responding tumors had more dysfunctional/exhausted T cells.
A new study reveals that a specific long non-coding RNA named SAMMSON interacts with protein CARF in growing melanoma cells, rewiring their protein synthesis networks and promoting cell growth. This interaction helps melanoma cells avoid inducing cell death when they experience abnormalities in ribosome synthesis.
Researchers at VIB and KU Leuven uncovered a critical role of the long non-coding RNA SAMMSON in boosting protein synthesis, enabling unrestrained cell growth. The study identifies SAMMSON as an essential step in melanoma initiation.
Researchers developed a new combination treatment that flips the switch on melanoma cells by targeting Bcl-2, MCL-1, and DRP-1 proteins. The approach killed melanoma cells and cancer stem cells in laboratory tests, offering an alternative option for patients who don't respond to current treatments.
A study found that cancer stem cells with MHC Class I molecules upregulate and retain CDK1 protein, allowing them to initiate tumor growth. Sox2 transcription factor plays a key role in maintaining their stemness.
Researchers from the University of Bath have identified the genetic basis for iridophore formation in zebrafish, a process that allows shoals to flash silver. The study used a combination of genetic techniques and mathematical modeling to pinpoint key genes driving this complex process.
Scientists have found an old antibiotic that selectively kills cells producing high levels of ALDH1 in melanoma tumors. The therapy shows promise for complementing existing treatments and may offer a new approach to targeting drug resistance.
The article addresses provoking questions in melanoma immunotherapy, cancer systems biology, and medical oncology. Researchers focus on understanding pigmentation and pigmentary diseases through big data science, collaborative team science, and individualized medicine.
Researchers found that loss of HAPLN1 protein in older patients creates a permissive environment for tumor cells to escape and metastasize. The study suggests that targeting HAPLN1 may be a new therapeutic avenue for improving long-term survival in melanoma patients.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that cancer cells redirect energy production when lactate dehydrogenase is inhibited, instead relying on glutamine to sustain growth and survival. This discovery identifies a potential new target for melanoma treatment by targeting the ATF4-signaling pathway.
Researchers developed a new cancer vaccine that boosts the immune system's ability to fight cancers, suggesting increased chances of recovery in cases where drug therapy alone is not working. The vaccine, called Diprovocim, was shown to produce a complete response in treating melanoma and preventing recurrence.
A natural plant compound called FR900359 has been identified as a potential treatment for uveal melanoma, shutting down the overactive signaling that drives cell growth. The compound traps G alpha q in its inactive state, preventing tumor cell growth and potentially reversing cancer-like changes.
Researchers have discovered that a distinct glycan feature, blood group I-antigen or 'I-branches', plays a central role in regulating both human B cell signaling/activation and melanoma aggressiveness. This finding has significant implications for immunomodulation and anti-cancer treatments.
Researchers found that adding retinoic acid to standard-of-care treatment for melanoma can turn off myeloid-derived suppressor cells (MDSCs) that resist immune treatments, leading to increased immune system activity. The study showed a safe and promising strategy to target MDSCs, which could be a useful addition to immunotherapies for ...
The article reviews existing novel approaches for automating melanocytic skin lesions diagnosis, highlighting success and shortcomings. Recommendations are made to reduce complexity and protracted computation by favoring better classification models over feature selection.
Researchers at Dana-Farber Cancer Institute found biomarkers in melanoma that can help tailor immunotherapy treatments. The study suggests that some patients with advanced melanoma may not benefit from combination therapy, but could do well with single-agent treatment.
Researchers at University of California - San Francisco have successfully genetically reprogrammed human immune cells known as T cells without the need for viruses to insert DNA. The new CRISPR-based method employs electroporation and offers a robust molecular 'cut and paste' system to rewrite genome sequences in human T cells.
UCSF researchers identified key genetic changes that transform benign moles into malignant melanoma, including mutations in DNA regulatory genes. They used CRISPR to recreate the steps of melanoma evolution in lab cells, revealing new biomarkers and potential targeted therapies.
Research reveals epigenetic factors, including EZH2 protein, play a crucial role in melanoma formation. The loss of cilia in pigment cells activates carcinogenic signaling pathways, leading to aggressive melanoma.
A team of researchers has identified a new family of enzymes that modify transfer RNAs in malignant melanoma, leading to addiction and resistance. Inhibiting these enzymes synergizes with targeted therapies to produce a strong anti-tumoral effect.
Researchers at The Wistar Institute found that older melanoma patients have a better response to immune checkpoint blockade therapy due to decreased regulatory T cells and increased killer CD8 T cells. Combining anti-PD1 and anti-CD25 treatment may improve response rates in younger patients.
The ILLUMINATE-204 trial shows an overall response rate of 38% with 2 complete responses, suggesting a promising strategy for treating patients with metastatic melanoma unresponsive to PD-1 therapy. The combination regimen is generally well-tolerated, with fewer than a quarter of patients experiencing immune-related toxicities.
Researchers have identified a new vulnerability in drug-resistant melanoma that can be exploited to selectively kill cancer cells. By targeting this vulnerability with vorinostat, resistant tumor cells are killed while sensitive cells remain alive.
Researchers found targeting telomerase and inhibiting mitochondrial function synergistically killed NRAS-mutant melanoma cells, inducing extensive cell death and DNA damage. Combination therapy also improved survival in a mouse model.
A new study found that individuals with malignant melanoma had a 61% lower risk of developing Alzheimer's disease compared to those without the condition. Basal cell and squamous cell carcinomas also showed significant reductions in AD risk, with correlations of 82% and 92%, respectively.
Researchers used single-cell imaging to study how melanoma cells evade drug action and acquire resistance to BRAF-inhibitor dabrafenib. The study found that 10% of treated cells reactivated the MAPK signaling pathway within 2-3 days, allowing them to signal through the pathway even in the presence of BRAF inhibition.
Researchers at UCLA have identified four distinct subtypes of melanoma with varying levels of sensitivity to ferroptosis, a type of self-inflicted cell death. These findings suggest new treatment approaches for dedifferentiated melanomas by combining ferroptosis-inducing drugs with multiple cancer therapies.
A study published in Science Translational Medicine reveals that macrophages suppress the activity of CD8 T cells, a type of immune cell that recognizes and kills melanoma cells. By disrupting macrophages, researchers found improved efficacy for immunotherapy in experimental models of melanoma.
A new study discovered an antibody that can prevent tumors from shedding proteins the immune system uses to identify and attack them. In mouse models of melanoma and lung cancer, this antibody increased natural killer cell infiltration into tumors, reducing their load.
A study published in Clinical Cancer Research demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. The research found that a modified telomerase substrate impaired telomere dysfunction and induced cell death in melanoma cells, suggesting a potential therapeutic strategy.
A dietary supplement commonly used to strengthen joints can also speed the growth of a type of melanoma, according to preclinical research. Chondroitin sulfate boosts growth in melanoma cells carrying the V600E mutation, but not other types, and may pose risks for people with elevated melanoma risk.
A team of international researchers has successfully stopped the growth of malignant melanoma by targeting epigenetic marks on DNA. By blocking enzymes responsible for erasing these marks, they reactivate a natural protective mechanism called cellular senescence, which prevents mutated cells from dividing and forming tumors.
Researchers have found a new mechanism of immunotherapy resistance that appears to be reversible, potentially enhancing the effect of current therapies. The approach targets a signaling pathway within the tumor microenvironment, which is manipulated by melanomas to silence dendritic cells.
A study found that desmoplastic melanoma patients respond significantly to anti-PD-1/PD-L1 therapies, with a 70% response rate. The tumors have high levels of DNA mutations and pre-existing immune cells necessary for an immune response.
A type of soil-dwelling bacterium produces a molecule that induces death in melanoma cells by targeting mitochondria. The molecule, mensacarcin, shows powerful anti-proliferative effects and can activate pathways to apoptosis, or programmed cell death.
Researchers have developed a novel compound called Corin that specifically targets epigenetic changes in melanoma cells, potentially leading to significant improvements in treatment outcomes. The new compound inhibits the growth of melanoma cells by targeting specific proteins involved in epigenetic modifications.
A novel compound omaveloxolone has been shown to restore immune response in patients with melanoma, improving antitumour responses when combined with checkpoint inhibitors. The study found a 57% overall response rate in patients who had not received prior checkpoint inhibitor treatment.
Researchers found seven genes with altered expression in melanoma patients, which could serve as biomarkers for diagnosis and therapeutic targets. The synthetic compound DM-1 induces cell death by increasing the expression of TOP-1 and ADK genes.
A study by UMMS researchers has identified a protein called GDF6 as a primary role in metastatic melanoma, found to be expressed in 80% of human melanomas and correlated with increased melanoma growth and spread. The findings offer new therapeutic potential for treatment-resistant skin cancer.